E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to severe ulcerative colitis. |
|
E.1.1.1 | Medical condition in easily understood language |
A chronic disorder characterized by inflammation of intestinal mucosa, primarily the colon, as well as the rectum. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009900 |
E.1.2 | Term | Colitis ulcerative |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to explore the efficacy of orally administered BBT-401-1S in inducing a clinical response in subjects with active UC. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are: • to assess the safety and tolerability of orally administered BBT-401-1S • to explore additional measurements of the efficacy of orally administered BBT-401-1S in inducing endoscopic and clinical remission. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subjects must satisfy all the following criteria at the screening visit, unless otherwise stated: 1. Male or female, of any race, ≥18 and ≤60 years of age. a. Females will not be pregnant or lactating. b. Females of childbearing potential will agree to abide by the contraception requirements from the time of signing the informed consent form (ICF) until 3 months after the last dose of study drug. c. Males will agree to abide by the contraception requirements from Day 1 until 3 months after the follow-up visit. 2. Have been diagnosed with active UC for ≥3 months prior to Day 1, as determined by clinical and endoscopic evidence and documented in a histopathology evaluation. 3. Have a total Mayo score ≥6, an endoscopic subscore ≥2, rectal bleeding subscore ≥1, and a stool frequency subscore ≥1, regardless of standard of care history. 4. Able to comprehend and willing to voluntarily sign an ICF and to abide by the study restrictions. |
|
E.4 | Principal exclusion criteria |
Subjects will be excluded from the study if they satisfy any of the following criteria at the screening visit, unless otherwise stated: 1. Have received: a. intravenous corticosteroids, rectally administered corticosteroids, or rectally administered 5-aminosalicylic acid within 3 weeks, or b. Janus kinase (JAK) inhibitors within 2 weeks, or c. cyclosporine, mycophenolate, tacrolimus, or methotrexate within 5 weeks, or d. anti-TNF-α biologics within 9 weeks, or e. any other biologics (including ustekinumab and vedolizumab) for the treatment of UC within 12 weeks. 2. Have received orally administered azathioprine or 6-mercaptopurine that has been stable for <8 weeks. Doses of oral drugs must remain stable until the last dose of study drug. 3. Have received orally administered 5-aminosalicylic acid, sulphasalazine, or low-dose corticosteroids (prednisolone ≤20 mg/day or equivalent) that have been stable for <5 weeks. Doses of oral drugs must remain stable until the last dose of study drug. 4. Have received any other concomitant medications for UC that have been stable (ie, have not started dosing with a new drug or had a change to their dosing regimen) for <7 days or 5 half-lives, whichever is longer. 5. Have Crohn’s disease, indeterminate colitis, ischaemic colitis, fulminant colitis, toxic megacolon, chronic (as determined by the investigator) pancolitis, confined proctitis (distal, ≤15 cm), or symptomatic intestinal stenosis. 6. Have a history of extensive colonic resection (subtotal or total colectomy) or are anticipated to require surgical intervention for UC. 7. Have an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine. 8. Have a positive test for Clostridium difficile, or have evidence of treatment for Clostridium difficile infection or other pathogenic bowel infection within 60 days or for another intestinal pathogen within 30 days prior to Day 1. 9. Have active infection with the human immunodeficiency virus or hepatitis B or C viruses. 10. Have clinically significant active extraintestinal infection (eg, pneumonia, pyelonephritis). 11. Have, in the opinion of the investigator, clinically significant abnormal vital signs, physical examination findings, or 12-lead electrocardiograms (ECGs) at screening or Day 1. 12. Have a history of any disease or condition (including mental and emotional conditions) that, in the opinion of the investigator (or designee), would affect participation in this study. 13. Have clinically significant abnormal liver function tests, including: a. estimated glomerular filtration rate ≤50 mL/min/1.73m2 b. alanine aminotransferase or aspartate aminotransferase >2 × the upper limit of normal (ULN) c. direct bilirubin >1.5 ULN. Note: Liver function tests may be repeated once, at the discretion of the investigator (or designee). 14. Have other clinically significant abnormal clinical laboratory results that, in the opinion of the investigator, preclude participation in the study, including: a. platelet count <100,000/μL b. haemoglobin <8.5 g/dL c. neutrophils <1500/μL d. lymphocytes <500/mm3 e. absolute white blood cells count <3000/μL. Note: Clinical laboratory evaluations may be repeated once, at the discretion of the investigator (or designee). 15. Have participated in a clinical study involving administration of an investigational drug in the past 30 days prior to Day 1. 16. Have previously participated in any study of BBT-401-1S. 17. In the opinion of the investigator (or designee) or the sponsor, should not participate in this study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the clinical response rate at Day 57, as measured by a reduction of ≥3 points and ≥30% improvement from baseline of total Mayo score, which includes a decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore ≤1. The primary safety endpoints are AEs and SAEs. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy endpoints are: • clinical remission at Day 57, as measured by a total Mayo score of ≤2 points, with no individual subscore exceeding 1 point • achievement of endoscopic remission at Day 57, as measured by a Mayo endoscopic subscore of 0 or 1. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Korea, Republic of |
New Zealand |
Ukraine |
United States |
Poland |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last patient in the clinical study (LVLP). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |